Article
Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumors.
Journal of clinical pharmacology - 1 Sept 2013
Denton Cathrine L, Minthorn Elisabeth, Carson Stanley W, Young Graeme C, Richards-Peterson Lauren E, Botbyl Jeffrey, Han Chao, Morrison Royce A, Blackman Samuel C, Ouellet Daniele
Abstract excerpt
Dabrafenib is an orally bioavailable, potent, and selective inhibitor of human wild-type BRAF and CRAF kinases as well as mutant forms of BRAF kinase. The aim of this phase 1, single-center, open-label study in four patients with BRAF mutation-positive solid tumors was to determine the absolute b...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.